10x Genomics stock slides premarket after insider sales filing as traders eye next catalyst
10x Genomics shares fell 3.3% to $21.40 in premarket trading Friday after CEO Serge Saxonov and CFO Adam Taich disclosed stock sales tied to vested restricted units. The drop follows a 12.6% surge in the prior session. Investors are awaiting a March 3 management appearance for updates on demand.